Literature DB >> 3119711

Production of a mouse-human chimeric monoclonal antibody to CD20 with potent Fc-dependent biologic activity.

A Y Liu1, R R Robinson, E D Murray, J A Ledbetter, I Hellström, K E Hellström.   

Abstract

Mouse monoclonal antibody 2H7 recognizes the CD20 cell surface phosphoprotein that is expressed in normal as well as malignant B cells. CD20 may be a useful target for therapy of B cell lymphomas, since damaged normal B cells can be replaced by their antigen-negative precursors. Monoclonal antibody 2H7 is an IgG2b (kappa) immunoglobulin which cannot mediate antibody-dependent cellular cytotoxicity with human lymphocytes or complement-dependent cytotoxicity with human serum. We have now generated a chimeric 2H7 antibody by substituting the mouse constant domains of 2H7 with the human gamma 1 and kappa domains. This new antibody has the same binding specificities as 2H7 but is highly effective in mediating antibody-dependent cellular cytotoxicity with human effector cells and complement-dependent cytotoxicity with human complement.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3119711

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  37 in total

Review 1.  Recombinant antibodies for the diagnosis and treatment of cancer.

Authors:  Jürgen Krauss
Journal:  Mol Biotechnol       Date:  2003-09       Impact factor: 2.695

2.  Serum half-life and tumor localization of a chimeric antibody deleted of the CH2 domain and directed against the disialoganglioside GD2.

Authors:  B M Mueller; R A Reisfeld; S D Gillies
Journal:  Proc Natl Acad Sci U S A       Date:  1990-08       Impact factor: 11.205

Review 3.  Antibody mediated targeting of radioisotopes, drugs and toxins in diagnosis and treatment.

Authors:  C H Ford; V J Richardson; V S Reddy
Journal:  Indian J Pediatr       Date:  1990 Jan-Feb       Impact factor: 1.967

Review 4.  Advances in targeted therapy for malignant lymphoma.

Authors:  Li Wang; Wei Qin; Yu-Jia Huo; Xiao Li; Qing Shi; John E J Rasko; Anne Janin; Wei-Li Zhao
Journal:  Signal Transduct Target Ther       Date:  2020-03-06

5.  Rituximab for non-Hodgkin's lymphoma: a story of rapid success in translation.

Authors:  Andrew M Harrison; Nassir M Thalji; Alexandra J Greenberg; Carmen J Tapia; Anthony J Windebank
Journal:  Clin Transl Sci       Date:  2013-10-03       Impact factor: 4.689

6.  Dose-related comparison of antibody-dependent cellular cytotoxicity with chimeric and native murine monoclonal antibody 17-1A. Improved cytolysis of pancreatic cancer cells with chimeric 17-1A.

Authors:  Y Haga; C L Sivinski; D Woo; M A Tempero
Journal:  Int J Pancreatol       Date:  1994-02

7.  Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis.

Authors:  M Q Xia; G Hale; M R Lifely; M A Ferguson; D Campbell; L Packman; H Waldmann
Journal:  Biochem J       Date:  1993-08-01       Impact factor: 3.857

8.  Therapeutic potential of chimeric and murine anti-(epidermal growth factor receptor) antibodies in a metastasis model for human melanoma.

Authors:  M Naramura; S D Gillies; J Mendelsohn; R A Reisfeld; B M Mueller
Journal:  Cancer Immunol Immunother       Date:  1993-10       Impact factor: 6.968

9.  Differential effects of a murine and chimeric mouse/human anti-interleukin-2 receptor antibody on human T-cell proliferation.

Authors:  B Rose; A Gillespie; D Wunderlich; K Kelley; J Dzuiba; D Shedd; K Cahill; B Zerler
Journal:  Immunology       Date:  1992-07       Impact factor: 7.397

10.  Mouse/human chimeric monoclonal antibody in man: kinetics and immune response.

Authors:  A F LoBuglio; R H Wheeler; J Trang; A Haynes; K Rogers; E B Harvey; L Sun; J Ghrayeb; M B Khazaeli
Journal:  Proc Natl Acad Sci U S A       Date:  1989-06       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.